- News Home
6 March 2014 1:04 pm ,
Vol. 343 ,
Magdalena Koziol, a former postdoc at Yale University, was the victim of scientific sabotage. Now, she is suing the...
Antiretroviral drugs can protect people from becoming infected by HIV. But so-called pre-exposure prophylaxis, or PrEP...
Two studies show that eating a diet low in protein and high in carbohydrates is linked to a longer, healthier life, and...
Considered an icon of conservation science, researchers at World Wildlife Fund (WWF) headquarters in Washington, D.C.,...
The new atlas, which shows the distribution of important trace metals and other substances, is the first product of...
Early in April, the first of a fleet of environmental monitoring satellites will lift off from Europe's spaceport in...
Since 2000, U.S. government health research agencies have spent almost $1 billion on an effort to churn out thousands...
- 6 March 2014 1:04 pm , Vol. 343 , #6175
- About Us
Problems Mount for Novartis's Hypertension Drug in Japan
30 September 2013 1:15 pm
An investigative committee under Japan's ministry of health has confirmed that data in scientific papers resulting from clinical trials of Novartis's blockbuster hypertension drug Diovan were manipulated, several media outlets have reported today. In its interim report, the committee also called for further investigation to determine if Novartis's use of the data to promote the drug constitutes false advertising that is prohibited by Japan’s pharmaceutical laws, according to NHK, the quasi-national broadcaster.
The ministry of health launched its investigation in August after Kyoto Prefectural University of Medicine, in Kyoto, and Jikei University School of Medicine, in Tokyo, reported finding evidence of data fabrication in papers reporting the results of clinical trials of Diovan, known generically as valsartan, conducted after it received marketing approval in Japan in 2000 for controlling hypertension. Those clinical trials sought to study whether the drug also helped prevent angina and stroke. Both of the investigations found that a former Novartis employee helped the two universities’ research teams with data analysis, though that person's link to the company was not disclosed in the papers. The investigations led to the retraction of several papers related to the trials. The lead researcher at the Kyoto school resigned; the Jikei team leader was disciplined. Three other universities that hosted Diovan trials have ongoing investigations.
As in the previous probes, the health ministry panel could not conclude who bears ultimate responsibility for the data fabrication. Officials of Novartis, based in Basel, Switzerland, and Novartis Pharma KK, the Japanese subsidiary, have apologized and pledged their cooperation in the continuing investigation.